Showing 501-510 of 8195 results for "".
Part 4, 1726 nm lasers: Handling referred patients who are already on different treatment regimens
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24342/Chapter 4 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about handling referred patients who are already on different treatment regimens.June Issue: Melanoma Updates - Epidemiology, Diagnostics, and Treatment
https://practicaldermatology.com/issues/may-june-2025/melanoma-updates-epidemiology-diagnostics-and-treatment/35917/In this article, we review the latest changes in melanoma incidence and mortality, highlight key disparities among minority populations, and summarize emerging trends in technology and treatment that are reshaping the future of melanoma care.Part 7, 1726 nm lasers: When a patient doesn’t improve: Doctors discuss “pearls” of wisdom
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24345/Chapter 7 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about when a patient doesn’t improve: Doctors discuss “pearls” of wisdom.Study Examines Association Between Childhood BMI and Risk of Developing IMSDs
https://practicaldermatology.com/series/dermwire-tv/study-examines-association-between-childhood-bmi-and-risk-of-developing-imsds/27004/In this week's DermwireTV, a new study examines the relationship between childhood BMI and skin diseases; phase 3 data sheds new light on dupilumab’s effect on inflammatory biomarkers in pediatric AD patients; and the president and CEO of Evolus discusses trends in the injectables market.FDA Approval for Delgocitinib
https://practicaldermatology.com/series/c-suite-chats/fda-approval-for-delgocitinib/36650/Robert Spurr, EVP, North America for LEO Pharma, discusses the importance of an FDA-approved option for treating moderate-to-severe chronic hand eczema in adults.Dr. Battle on Skin of Color Update and Minimizing, Treating Complications from Energy-Based Devices
https://practicaldermatology.com/topics/skin-of-color/dr-battle-skin-color-update-and-minimizing-treating-complications-energy-based-devices/28655/Eliot Battle, MD, discusses the growth of Skin of Color Update, minimizing and treating complications when treating patients of skin of color, and integrating energy-based devices into your practice.DermWire TV Extra: SDPA President Amber Blair, PA-C, Previews Her New Column
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-extra-sdpa-president-amber-blair-pa-c-previews-her-new-column/27001/Amber Blair, PA-C, president of the Society of Dermatology Physician Associates, discusses important initiatives that she plans to cover in her new quarterly column in Practical Dermatology.Noah Worcester 2024: Dr. Bettencourt on Beach Vacations
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-bettencourt-beach-vacations/24591/Miriam Bettencourt, MD, summarizes her lecture about problems that can be encountered during beach vacations at the 2024 Noah Worcester Dermatological Society meeting.DermWire TV: Maui Derm Highlights, Plus New and Emerging Treatments for HS and Acne
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-maui-derm-highlights-plus-new-and-emerging-treatments-for-hs-and-acne/20258/In this episode of DermWire TV, we recap the biggest news from Maui Derm 2024, including safety and efficacy studies on bimekizumab, deucravacitinib, and upadacitinib. Also from Maui Derm, Raj Chovatiya, MD, PhD, highlights new therapies to treat hidradenitis suppurativa and Julie Harper, MD, highliDermWireTV: Olumiant Approved for AA; Radiesse + Launch; Derms as Influencers; VCS
https://practicaldermatology.com/topics/practice-management/dermwiretv-olumiant-approved-for-aa-radiesse-launch-derms-as-influencers-vcs/20107/Olumiant (baricitinib) from Eli Lilly and Company is approved to treat adult patients with severe alopecia areata. Dermatologists rank as top influencers of consumers’ decisions to have cosmetic procedures, according to results of the American Society for Dermatologic Surgery (ASDS) Consumer Survey